상세 보기
초록
We investigated the effects of indacaterol on cough and phlegm in patients with stable chronic obstructive pulmonary disease (COPD). We performed a meta-analysis with five randomized controlled trials (RCTs) of indacaterol in stable COPD patients. The symptom severity was defined using the St. George's Respiratory Questionnaire (SGRQ). We analyzed patients treated with 150 mu g (n = 945) and 300 mu g (n = 832) out of 3,325 patients who completed the SGRQ from five RCTs. After a 12-week treatment of 150 mu g indacaterol, cough improvement was reported in 36.5% (316/866) of patients treated with indacaterol vs. 32.2% (259/804) patients treated with placebo (Relative Ratio [RR], 1.13; 95% confidence interval [CI], 0.99-1.29). Phlegm improvement was reported in 31.0% (247/798) of patients treated with indacaterol vs. 30.6% (225/736) of patients treated with placebo (RR, 1.01; 95% CI, 0.87-1.18). Dyspnea improvement was reported in 39.5% (324/820) of patients treated with indacaterol vs. 31.5% (237/753) patients treated with placebo (RR, 1.33; 95% CI, 1.03-1.71; P = 0.001, I-2 = 55.1%). Only dyspnea improvement was significant compared to placebo even at the 300 mu g indacaterol dose. Compared to placebo, a 12-week treatment of the long-acting beta-agonist, indacaterol might not have a significant effect on cough or phlegm in stable COPD.
키워드
- 제목
- Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials
- 저자
- Park, Jinkyeong; Lee, Jung Su; Rhee, Chinkook; Oh, Yeon-Mok
- 발행일
- 2015-10
- 유형
- Article
- 권
- 30
- 호
- 10
- 페이지
- 1453 ~ 1458
- 언어
- ENG
- 출판사
- 대한의학회
- 발행국가
- 대한민국
- 분량
- 6 페이지
- ISSN
- E 1598-6357
P 1011-8934